Patient Enrollment Paused in Phase 3 Trial of Tedopi in NSCLC
News
OSE Immunotherapeutics has temporarily paused patient enrollment in a Phase 3 clinical trial evaluating Tedopi (OSE2101) for non-small cell lung cancer (NSCLC), following a recommendation by an Independent Data Monitoring ... Read more